Developing Infectious Disease Strategies for the Developing World

Overview

Journal Annu Rep Med Chem

Specialty Biochemistry

Date 2020 Apr 15

PMID 32287466

Authors

Paul J Lee

Leonard R Krilov

Affiliations

Soon will be listed here.

Abstract

This chapter discusses various drugs for human influenza A (H5N1) and multidrug-resistant mycobacterium tuberculosis (MDR-TB). The H5N1 avian influenza does not presently meet the criteria of an antigenically shifted strain. It is presently an avian strain that has not undergone reassortment with a human strain and is not well adapted to humans. H5N1 isolates are resistant to the M2 inhibitors amantadine and rimantadine; these antivirals do not have a role for the treatment or prophylaxis against the strain. The neuraminidase inhibitors, oseltamivir and zanamivir, have activities against the human H5N1 isolates; however, recent data suggest that higher doses for longer periods may be required to be effective. Oseltamivir is an oral agent approved for prophylaxis and the treatment of influenza infections. Zanamivir is delivered topically to the respiratory tract with similar indications. The drugs discussed in the chapter for MDR-TB fall into three categories-quinolones, nitroimidazoles, and pyrroles. Drugs such as moxifloxacin are methoxyfluoroquinolones, which are already available and approved for the treatment of acute respiratory infections, such as community-acquired pneumonia, intra-abdominal infections, acute sinusitis, and skin infections. Gatifloxacin 5, is another methoxyfluoroquinolone that is in clinical development for tuberculosis treatment.

References

Sulochana S, Rahman F, Paramasivan C . In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother. 2005; 17(2):169-73. DOI: 10.1179/joc.2005.17.2.169. View

Fraser A, Paul M, Attamna A, Leibovici L . Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2006; (2):CD005435. PMC: 6532726. DOI: 10.1002/14651858.CD005435.pub2. View

Codecasa L, Ferrara G, Ferrarese M, Morandi M, Penati V, Lacchini C . Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med. 2006; 100(9):1566-72. DOI: 10.1016/j.rmed.2006.01.002. View

Lenaerts A, Gruppo V, Marietta K, Johnson C, Driscoll D, Tompkins N . Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005; 49(6):2294-301. PMC: 1140539. DOI: 10.1128/AAC.49.6.2294-2301.2005. View

van Riel D, Munster V, de Wit E, Rimmelzwaan G, Fouchier R, Osterhaus A . H5N1 Virus Attachment to Lower Respiratory Tract. Science. 2006; 312(5772):399. DOI: 10.1126/science.1125548. View

Andries K, Verhasselt P, Guillemont J, Gohlmann H, Neefs J, Winkler H . A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2004; 307(5707):223-7. DOI: 10.1126/science.1106753. View

Rook G, Dheda K, Zumla A . Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine. 2005; 23(17-18):2115-20. DOI: 10.1016/j.vaccine.2005.01.069. View

Nuermberger E, Tyagi S, Williams K, Rosenthal I, Bishai W, Grosset J . Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med. 2005; 172(11):1452-6. PMC: 1853317. DOI: 10.1164/rccm.200507-1047OC. View

Dye C, Watt C, Bleed D, Hosseini S, Raviglione M . Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005; 293(22):2767-75. DOI: 10.1001/jama.293.22.2767. View

10.

Lalloo U, Naidoo R, Ambaram A . Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med. 2006; 12(3):179-85. DOI: 10.1097/01.mcp.0000219266.27439.52. View

11.

Stover C, Warrener P, VanDevanter D, Sherman D, Arain T, Langhorne M . A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405(6789):962-6. DOI: 10.1038/35016103. View

12.

Beigel J, Farrar J, Han A, Hayden F, Hyer R, de Jong M . Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005; 353(13):1374-85. DOI: 10.1056/NEJMra052211. View

13.

Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong B, Narayanan S . Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006; 103(8):2869-73. PMC: 1413851. DOI: 10.1073/pnas.0511240103. View

14.

de Jong M, Tran T, Truong H, Vo M, Smith G, Nguyen V . Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353(25):2667-72. DOI: 10.1056/NEJMoa054512. View

15.

Gupta R, Nguyen-Van-Tam J . Oseltamivir resistance in influenza A (H5N1) infection. N Engl J Med. 2006; 354(13):1423-4. DOI: 10.1056/NEJMc060077. View

16.

Reed S, Lobet Y . Tuberculosis vaccine development; from mouse to man. Microbes Infect. 2005; 7(5-6):922-31. DOI: 10.1016/j.micinf.2005.03.011. View

17.

Cynamon M, Sklaney M . Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother. 2003; 47(8):2442-4. PMC: 166105. DOI: 10.1128/AAC.47.8.2442-2444.2003. View

18.

Yen H, Monto A, Webster R, Govorkova E . Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005; 192(4):665-72. DOI: 10.1086/432008. View

19.

Treanor J, Campbell J, Zangwill K, Rowe T, Wolff M . Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354(13):1343-51. DOI: 10.1056/NEJMoa055778. View

20.

McShane H, Pathan A, Sander C, Goonetilleke N, Fletcher H, Hill A . Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb). 2005; 85(1-2):47-52. DOI: 10.1016/j.tube.2004.09.015. View